

# Supplementary Information

## MCM-41 for Meloxicam Dissolution Improvement: *in vitro* Release and *in vivo* Bioavailability Studies

Asaad F. Hassan,<sup>\*,a</sup> Sally A. Helmy<sup>b,c</sup> and Ahmed Donia<sup>d</sup>

<sup>a</sup>Department of Chemistry, Faculty of Science, Damanhour University, 22511 Damanhour, Egypt

<sup>b</sup>Department of Pharmaceutics, Faculty of Pharmacy, Damanhour University, 22511 Damanhour, Egypt

<sup>c</sup>Department of Clinical and Hospital Pharmacy, Faculty of Pharmacy, Taibah University,  
41321 AL-Madinah, AL-Munawarah, Kingdom of Saudi Arabia

<sup>d</sup>Department of Pharmaceutical Technology, Faculty of Pharmacy, Tanta University, 31511 Tanta, Egypt




Figure S1. FTIR (KBr) spectra for F1 and F3.




Figure S2. TGA for F1 and F3.




Figure S3. XRD patterns for F1 and F3.




Figure S4. Nitrogen adsorption/desorption isotherms (a) and linear BET plot (b) at  $-196\text{ }^{\circ}\text{C}$  onto F1 and F3.





Figure S5. SEM images for F1 (a) and F3 (b).